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ABSTRACT
TRPV1 MRNA IS DIFFERENTIALLY EXPRESSED IN DIFFERENT VERTEBRAL
LEVELS OF RAT DORSAL ROOT GANGLIA FOLLOWING
SCIATIC NERVE INJURY

By
Bree Zeyzus Johns
May 2009

Thesis Supervised by John A. Pollock, Ph.D.
Transient Receptor Potential Vanilloid 1 plays an important role in the pain
pathway. TRPV1 is expressed in primary afferent nociceptors and acts as a transducer
for noxious stimuli; including capsaicin, toxins and noxious heat. TRPV1 protein
expression increases in inflammatory and neuropathic pain models, but transcriptional
regulation of TRPV1 remains unclear. In the present study, TRPV1 mRNA levels were
measured in Dorsal Root Ganglia pertaining to the third, fourth and fifth vertebral levels
of the lumbar spine following chronic constriction injury of the sciatic nerve in rats.
TRPV1 mRNA levels are shown to increase in lumbar dorsal root ganglia in response to
sciatic nerve injury. Moreover, the magnitude of change in TRPV1 mRNA level varies
with dorsal root ganglia level. These novel findings show that TRPV1 mRNA levels are
regulated in response to chronic nerve injury, and strengthen interest in this channel as a
specific target for pain therapy.
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Chapter 1
INTRODUCTION
1.1

The impact of pain on society: The Pain Paradox
Pain is an epidemic which affects an estimated 50 million Americans and costs

approximately US$61 billion in lost productivity and healthcare expenses per annum [1,
2]. This number rises each year as the occurrence of serious diseases such as heart
disease, AIDS, diabetes and arthritis also rise. Despite the substantial investment in
pharmaceutical research, common pain treatments have changed little over the last
several decades. New therapies for treating pain are needed.
Among the milieu of drug options presently available, two broad classes of drugs
stand out; the opioids and the non-steroidal anti-inflammatory drugs (NSAIDS). Opiod
drugs are commonly chosen as the first-line treatment for patients suffering from severe,
acute pain or from chronic pain associated with a long-term illness. Pure opioid agonists,
like oxycodone and morphine, principally function to increase analgesia [3]. It is
contended that they exert their action by binding all opioid receptors in the central
nervous system (CNS), and thus, are associated with a plethora of undesirable
pharmacological affects such as constipation, respiratory depression, and sleeplessness,
among others [3]. Tolerance and withdrawal occur and can pose serious clinical
problems for patients using opioid drugs for pain therapy.
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NSAIDS are typically used to treat moderate acute pain, inflammation, and
redness or are used in conjunction with opioids to treat chronic pain [4]. NSAIDS are
non-narcotic analgesics that exert their function in the peripheral nervous system by
inhibiting cyclooxegenase (COX) enzymes. COX-1 and COX-2 catalyze the production
of prostaglandins and other inflammatory and pain mediators. Similar to opioids,
NSAIDS are broadcast non-specifically throughout the body and, thus, are also
associated with many serious side affects [4].
Aside from the potential pharmacological complications, the efficacy of the
presently used therapies is under question. Opioids, NSAIDS, anti-epileptics and
tricyclic antidepressants fail to produce sustainable relief from chronic pain [1, 5]. This
so-called ‘pain paradox’ exemplifies the need for novel analgesic drug development.
Before our society can face this clinical challenge, however, we must expand our
knowledge of the molecular basis of pain. The purpose of this study is to help bridge this
gap between the basic biology of pain and a clinical application.

1.2

The physiology of pain and nociception
Metazoans are continuously bombarded with stimuli. These stimuli encounter the

peripheral receptors of sensory nerves, which innervate both tissues to the exterior and
those found inside the body. It is a requirement of an organism’s peripheral and central
nervous systems to process and coordinate the information in order to respond
accordingly. More specifically, it is essential to differentiate among stimuli that are
potentially tissue-damaging and those that are innocuous [6]. Higher eukaryotes have
evolved a protective mechanism in response to noxious stimuli that involves the
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generation of a highly unpleasant sensation. Once perceived by the brain, the painful
sensation causes the organism to take actions that will minimize exposure to the
threatening stimulus [7]. It is the action of nociceptors that initiates this protective alarm
bell.
In 1903, Charles Sherrington first coined the term nociception and defined it as
the ability of specialized neurons, which he later defined as nociceptive nerves or
nociceptors, in the peripheral nervous system (PNS) to sense a potentially damaging
stimulus [8,9].

In order to function purely as an alarm bell for harmful stimuli,

nociceptors have a high threshold and only respond to stimuli with sufficient energy to be
tissue-damaging [10]. Some nociceptors can be thinly myelinated, but the majority are
un-myelinated, slow propagating C fibers [10].
Nociceptors are a type of primary sensory neuron that are attuned to painful
stimuli. The cell bodies of nociceptors are found in dorsal and trigeminal ganglia and
have one major extension, which bifurcates into two projections; one extending to the
skin of the body and face, the mouth and the tongue, and the other into the CNS where it
synapses on nociceptive second order neurons [10,11]. Consequently, the nociceptor has
four functional components; the peripheral terminal which innervates the skin of the
target tissue and contains ion channels that transduce the injurious stimulus, the axon
which propagates the action potential to the central nervous system, the cell body which
is housed in dorsal root ganglia (DRG), and the central terminal, where information is
transferred to higher order neurons in the CNS (Fig 1A) [10].
Upon activation of nociceptive ion channels by a noxious stimulus, the peripheral
terminals become depolarized. The influx of Na + and Ca2+ causes the interior of the
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neuron to become more positive. If the stimulus is strong enough and the influx of
cations is sufficient to surpass the voltage threshold of the neuron, an action potential is
initiated at the axon hillock. The action potential is propagated along the length of the
axon until it reaches the central terminal. At the central terminal, substance P and/or
other neuropeptides are released, and these bind their receptors located in the plasma
membrane of the synapsing second order neuron (Fig 1B). The signal is transferred to
higher brain centers, where it is ultimately integrated and perceived as pain.

4
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Figure 1. Nociceptor Structure and Mechanism.
(A) Structure of a nociceptor. Peripheral terminal innervates the skin and
transduces the noxious stimulus. Axon propagates the action potential. Cell
body is located in the Dorsal Root Ganglion (DRG). Central terminal
transfers the signal to higher order neurons.
(B) Mechanism of nociception. Ion channels involved in the transduction of
noxious stimuli depolarize the interior of the peripheral terminal causing a
generator potential. An action potential is initiated at the axon hillock, and is
propagated to the central terminal by way of the axon. Central terminal
releases neuropeptides in response, which either excite or inhibit the
synapsing second order nociceptive neuron.
Figure from reference 10.

5

B. Zeyzus Johns

1.3

The Transient Receptor Potential (TRP) protein superfamily
A number of ion channels have been identified that are involved in the

nociceptive pathway. Among them is a class of proteins called the Transient Receptor
Potential (TRP) proteins. TRP proteins are generally defined as cation-permeable ion
channels that share the same general membrane topology; six-transmembrane (6TM)
polypeptide units flanked by an N- and C-terminus, a conserved TRP domain and a poreloop between segments 5 and 6 [12,13]. Aside from sharing this general function and
structure, TRP channels are otherwise highly diverse in their pharmacology and
physiology.
In the human genome, 28 TRP genes have been identified [6]. These genes are
further classified into 6 subfamilies based on sequence homology: TRPA, TRPC, TRPM,
TRPML, TRPP and TRPV [14]. The nomenclature was unified by members of the TRP
Nomenclature Committee [15]. Members of the TRPA subfamily were named for their
structural similarity to the ankyrin protein. The TRPC, or TRP-Canonical, subfamily is so
named because these proteins are the most highly related to the prototype Drosophila trp
[16, 17]. The TRPV subfamily is named after the original designation for its first
mammalian member, Vanilloid Receptor 1. The TRPM family was named for its
founding member, melastatin (MLSN), which is encoded by a predicted tumorsuppressor gene [18]. TRPML is named for the human mucolipin 1 protein. Lastly,
TRPP is so named for its founding member, PKD2 [19].
TRP protein channels are activated by a variety of different physical stimuli; to
include noxious, chemical, thermo- and mechanostimuli [14]. Following their activation,
TRP channels transduce the signal like all primary sensory neurons. An influx of cations
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crosses the plasma membrane, subsequently raising the intracellular Ca2+ and Na+
concentrations. This depolarization event alters the voltage properties of the neuron such
that a threshold value is reached, and an action potential is propagated to the CNS. The
signal is sent to higher brain centers where it is integrated with other signals, and is
ultimately perceived [14].
A subset of TRP channels are expressed in primary afferent nociceptors and in
pain sensing ganglia where they act as transducers for physical and noxious stimuli
(Table 1) [5]. These pain-sensing TRPs, which include TRPV1-4, TRPA1 and TRPM8,
are highly diverse in their sequence homology, modalities, regulation and expression; yet,
there is evidence to support their unique involvement in the generation of pain [5, 20-29].
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Table 1. Pain Sensing TRP Proteins.

**Information for table from references 5 and 6. Abbreviations: Dorsal Root Ganglia (DRG), Trigeminal
Ganglia (TG), nitric oxide (NO).
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1.4

Transient Receptor Potential Vanilloid 1 (TRPV1)
Among the pain-sensing TRPs, TRPV1 (also called vanilloid receptor 1, VR1 or

the capsaicin receptor) is the most well characterized member. It was the first receptor of
the TRPV family cloned [20], and is so named because of it’s activation by the pungent
ingredient in hot peppers, capsaicin. Aside from activation by exogenous vanilloid
ligands, this polymodal ion channel is also activated by noxious heat (≥43°), endogenous
lipid signaling molecules (eicosanoids), and low pH [19, 30, and 31]. More recently,
TRPV1’s activation by spider and jellyfish toxins [21, 22], camphor [31] and allicin [32,
33] has also been reported. TRPV1 was originally described in small to mediumdiameter neurons in dorsal root, trigeminal and nodose ganglia [20, 31]. It has since been
identified in other non-neural tissues, yet it is most highly expressed in sensory neurons
[34].
The role of the TRPV1 channel in models of acute pain is well established [23-25,
35-37]. Capsaicin induces nocifensor, or pain-like, behaviors and hyperalgesia
(reduction of pain threshold) in rodents and humans [35, 36]. Studies involving TRPV1
knock-down and knock-out phenotypes support a role for TRPV1 in the development of
pain [23-25]. Of particular interest, trpv1(-/-) mice experience a reduced response to
noxious heat and pungent vanilloid compounds following injection of tissue-damaging
preparations; including complete Freund’s adjuvant (CFA) and carrageenan into the
plantar surface of the hind paw. CFA is a preparation of dried mycobacterium and
carrageenan is a red seaweed extract. TRPV1 antagonists, including SB-705498 and
A425619, have proven successful in pre-clinical trials using acute inflammatory pain
models [38, 39].
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In models of neuropathic pain, where a pathological condition arises from a nerve
or group of nerves, it is contended that TRPV1 is a key mediator. In rat chronic pain
models involving complete ligation of the L5 spinal nerve and partial ligation of the
sciatic nerve, undamaged neurons reportedly experience an increase in TRPV1 protein
expression [40]. Spinal TRPV1 protein levels ipsilateral to the nerve injury increase
significantly following chronic constriction injury of the sciatic nerve [41]. A sustained
increase in TRPV1 protein levels is also observed in rat DRG following injection of
complete Freund’s adjuvant (CFA) into the plantar surface of the hind paw [42]. The
contribution of TRPV1 to pathophysiological conditions such as irritable bowel
syndrome [43,44], acute pancreatitis [45,46], asthma and arthritis [47] is complex and
likely explained by excessive release of neuropeptides from TRPV1-expressing neurons,
which promotes inflammation [45].
There is evidence that TRPV1 protein expression but not mRNA levels increase
in dorsal root ganglia (DRG) 7 days after production of chronic constriction injury on the
sciatic nerve in rats [27,42]. These studies assayed for changes in mRNA level from
combined DRG dissected from multiple vertebral levels; however, afferent contributions
from the sciatic nerve to lumbar DRG are not equal (Figure 2) [48, 49]. Moreover,
animals with CCI reportedly experience maximum pain sensitivity 12 days post-surgery,
and thus, it is worth investigating gene expression at a later time point. Given variations
of the previous studies and the lack of knowledge in this regard, the following hypotheses
were formed: (1) TRPV1 mRNA levels in DRG are altered in response to sciatic nerve
injury, (2) the magnitude of change in TRPV1 mRNA level varies with DRG level due to
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varying afferent contributions from the sciatic nerve, and (3) changes in TRPV1 gene
expression may be time-dependent.
Here I report the novel results of my thesis work. TRPV1 mRNA levels in lumbar
Dorsal Root Ganglia are increased in response to chronic constriction injury-induced
neuropathic pain. Additionally, I also demonstrate that the magnitude of change in
TRPV1 transcript level varies with Dorsal Root Ganglia level.
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Figure 2. Rat Neural Anatomy.
Dorsal view of rat spinal cord and associated neural structures.
Cell bodies of neurons in Dorsal Root Ganglia (DRG) pertaining to the third, fourth
and fifth vertebral level of the lumbar spine project axons that give rise to spinal
nerves. These spinal nerves join to form the sciatic nerve at the mid-thigh level. L4
and L5 DRG contain 98-99% of the somata of neurons projecting to the sciatic nerve,
and L3 only contains 1.2% of total somata. Contribution of L6 to the sciatic nerve is
variable (dotted line), and at most represents 0.4% of total somata. Autoclips for
wound closure are in place at the level of mid-thigh following chronic constriction
injury of the sciatic nerve (refer to methods).
Artwork kindly provided by Mr. Robert Hoggard.
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Chapter 2
MATERIALS AND METHODS
2.1

Production of the chronic constriction injury
This study was approved by the Institutional Animal Care and Use Committee of

Duquesne University. A total of 18 adult male Sprague-Dawley rats (Hilltop Lab
Animals, Inc., Scottdale, PA, 170g) were used for the experiments.
The chronic constriction injury (CCI) method, as described by Bennett and Xie,
was used to induce the neuropathic pain state [50]. This chronic pain model is used in the
laboratory of committee member, Dr. David Somers, to mimic chronic regional pain
syndrome II (CPSII) in humans [51-54]. CPSII is a pain syndrome that develops often in
an extremity following injury to a peripheral nerve. In the rat, this procedure causes the
hind paw on the operated side to develop a reduced pain threshold to thermal and
mechanical stimulation, as well as postural indications of ongoing pain. Dr. Somers is
well established with this procedure, and provided training of all the skills necessary to
reproduce it independently.
Rats were deeply anesthetized with sodium pentobarbital (50mg/kg) by
intraperitoneal injection, and the anesthesia was assessed by both a tail pinch and the leg
withdrawal reflex. Additional doses (approximately 6mg/kg) of the anesthetic were
supplemented as needed. Briefly, the right thigh of each animal was opened to expose
13
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the sciatic nerve. The right sciatic nerve was selected purely for technical reasons. Four
4.0 chromic gut sutures were tied loosely around the sciatic nerve such that the nerve was
not overly constricted under the ligature and perfusion of the nerve distal to the ligature
site was not altered [50]. Special care was taken to space the ligatures 1mm apart from
one another to avoid over-constriction of the nerve in a single area, as this could inhibit
propagation of pain signals to the CNS. The wound was closed in layers, with 4.0 silk
sutures to close the muscle and autoclips to close the skin. Following surgery, weight
measurements of the chronic pain animals were measured bi-weekly to ensure the
animals’ health and well being. Photographs of the CCI surgical procedure can be found
in Figure 3 (A-E).
Two groups of control rats were used in this study; a uni-lateral sham-operation
group (sciatic nerve exposure without ligation) and an un-operated group. The latter only
received anesthetic.
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Figure 3. Chronic Constriction Injury Surgery.
(A) Pre-surgery; Anesthetized rat with surgical area, right thigh, shaved and
sterilized (beta-iodine solution).
(B) Surgery; Sciatic nerve exposed.
(C) Post-surgery; Rat still under anesthesia following surgery. Skin superficial to
wound closed with autoclips.
(D) Rat sciatic nerve with four 4.0 chromic gut sutures in place (see box inset). The
lack of perfusion to the nerve and surrounding muscle that is evident is a result of
the rat’s post-mortem status.
(E) Sketch of rat sciatic nerve with four sutures in place. The spinal cord and the
L5 spinal nerve intersecting with L4 are shown. Intersection of these nerves forms
the sciatic nerve at mid-thigh level.
Photographs A-C kindly provided by Karl Andersen.
Artwork (E) kindly provided by Mr. Robert Hoggard.
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2.2

Pain assessments
All rats underwent bi-lateral sensory testing for mechanical allodynia (pain

sensitivity to a non-painful, mechanical stimulus) and thermal hyperalgesia, both of
which are well documented symptoms of CCI-induced neuropathic pain [50]. Baseline
assessments were performed on all rats the same day as the CCI and sham operations, but
prior to the commencement of these procedures. To evaluate the development of chronic
pain over time, the tests were then repeated on all rat subjects 8 days post-surgery and
then again 11 days post-surgery. A timeline of this experimental design and the pain
assessment equipment are represented in Figure 4 (A-C).
Mechanical pain threshold was assessed by applying calibrated SemmesWeinstein monofilaments [52, 55, and 56] to the plantar surface of the animals’ hind
paw, specifically in the cutaneous region that is innervated exclusively by the sciatic
nerve [52, 57]. Briefly, rats were placed on a metal grid that was covered with a
Plexiglas lid (Figure 4B). The filaments (0.41, 1.2, 3.63, 8.51, 15.13g) were applied in
ascending order, from the lowest caliber filament to the highest, and the total number of
paw withdrawals from each stimulus was recorded for both the left and right hind paw.
Each paw received a total of 10 pushes from each filament (two trials separated by 5 min,
5 applications per trial, 3 s per each application). The testing was terminated when the
largest caliber filament was tested or when the rat withdrew from all 10 pushes for a
single filament.
The linear regression method was used to estimate each rat’s 50% withdrawal
threshold, or the force (g) at which the rat withdrew a paw 5 of 10 total pushes. If the rat
failed to respond to any filaments used, 15.13g was recorded as the 50% withdrawal
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threshold (WT) [52]. On three occasions, an animal withdrew its paw from a caliber with
intermediate thickness in the middle of a test series, and then the same rat did not respond
whatsoever to the thickest (15.13g) caliber applied thereafter. This situation is often a
display of the rat’s anxiety to the test, and does not reflect a positive, painful response.
When encountered, the zero strategy that has been used by Dr. Somers was used. The
zero representing no paw withdraws from the thickest caliber filament was eliminated
from the analysis altogether, and the regression was run on the filaments of less force that
were applied before the first response. Thus, the 50% withdraw threshold is placed over
the value of the filaments where the animal most likely withdrew. Although I did not test
for the reliability of this strategy, Dr. Somers has repeated the behavior and regression
test over time and found it to be an extremely reliable method. A normalized difference
score was calculated for each rat at each time point using the following formula:

Normalized 50% withdrawal threshold (WT) = Post-Surgery (50% WT right paw
– 50% WT left paw) – Baseline (50% WT right paw – 50% WT left paw).

All normalized withdrawal thresholds for a given treatment group (un-operated control,
sham-operated control, CCI) at each time point were averaged, and the Kruskal-Wallis 1way ANOVA by Ranks Test was used to compare the means (P ≤ 0.05). The KruskalWallis value from each comparison was compared to the critical value of the chi-squared
distribution with 1 degree of freedom and alpha = 0.05. This value was determined to be
3.84.
Thermal pain threshold was assessed by withdraw latency from a radiant heat
source. Rats were placed on a temperature controlled plexi-glass surface in a plexi-glass
cubicle (Figure 4C). The heat source was a projector bulb from a slide projector that is
17
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attached to a timer and focused through a fixed diameter aperture. After habituation for a
period of 5 minutes, radiant heat was applied to the plantar surface of both the left and
right hind paws of the chronic constriction injury rats, the sham-operated and un-operated
control rats. Stimulus onset activated a timer that was controlled by a photocell that was
positioned to receive reflected light from the hind paw. Paw withdrawal interrupted the
photocell’s light and automatically stopped the timer. Each paw received a total of five
irradiations, with five minutes separating each irradiation. The latency to withdraw in
hundredths of a second was recorded. Twenty seconds was the maximum irradiation
time in order to prevent the glass from reaching a temperature that could burn the
animals’ hind paws. The five latency measurements obtained for each paw were
averaged in order to obtain a mean latency. Normalized withdrawal latency was
calculated for each rat at each time point using the following formula:

Normalized Withdrawal (WD) Latency = Post-Surgery (WD latency right paw –
WD latency left paw) – Baseline (WD latency right paw – WD latency left paw).

All normalized withdrawal latencies for a given treatment group (un-operated control,
sham control, CCI) at each time point were averaged, and the Kruskal-Wallis 1-way
ANOVA by Ranks Test was used to compare the means.
Nocifensor behaviors such as guarding the affected paw from the test surface and
excessive paw licking and lifting directly following application of each stimulus were
noted for all rats in the study. A table was created of the number of animals that
responded with a pain response at least one time while performing the mechanical and
thermal pain assessments. Guarding refers to prolonged contact avoidance between the
affected (right) hind paw and the test surface. Guarding was observed in rat subjects
18
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during the rest period (5 minutes) between trials of each test session. Rats displayed
guarding by lying on their left side with the affected right paw in a protected position
against their flank. Excessive right paw licking refers to the rat withdrawing a paw
quickly from a poke (mechanical) or the heat (thermal) and bringing the paw immediately
to their mouth to lick it. Paw lifting was recorded directly following the stimulus, and
was defined as withdrawing the right paw from the stimulus and holding it for a
prolonged period of time (5-10 sec) before lowering the paw to the test surface.
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Figure 4. Animal Work.
(A) Experimental design; Baseline pain assessments were performed on unoperated controls, sham controls and CCI rats on day 0 prior to CCI and sham
surgeries. Pain assessments were repeated 8 and 11 days post-surgery. Dorsal root
ganglia were dissected from half of the animals (3 CCI, 3 sham-operated controls,
3 un-operated controls) 9 days post-surgery, and DRG from the remaining half
were dissected on day 12.
(B) Mechanical pain assessment; Rats positioned on metal grid. Mechanical
allodynia was tested by poking (Semmes-Weinstein monofilaments) the plantar
surface of the rats’ hind paws from beneath the grid.
(C) Thermal pain assessment; Rats positioned on temperature-controlled plexiglass. Thermal hyperalgesia is tested by applying radiant heat (seen below right
rat) to the plantar surface of hind paws. Withdraw latency measured in ms.
Photographs kindly provided by Karl Andersen.

20

B. Zeyzus Johns

2.3

Dorsal Root Ganglia dissection
Ipsilateral and contralateral lumbar Dorsal Root Ganglia (DRG) 3-5 were

dissected from 3 CCI rats, 3 sham-operated and 3 un-operated control rats 9 days postsurgery via laminectomy. Briefly, animals were anesthetized with sodium pentobarbital
(50mg/kg) intraperitoneally. A mid-line incision was made dorsally from the level of the
cervical vertebrae to the sacrum. The spinous and lateral processes of the lumbar
vertebrae were exposed, and the spinous processes were clipped with medical Rongeurs.
The dorsal lumbar vertebrae were flattened with a Dremel drill, and the spinal column
was carefully opened, exposing the spinal cord and DRG (Fig 5). Ganglia were rapidly
removed and submerged immediately into RNAlater solution (Qiagen). Twelve days
post-surgery, DRG were collected in the same fashion from the remaining rats (3 CCI, 3
sham-operated, 3 un-operated). Rats were terminated via cervical dislocation after
completion of DRG extraction. DRG samples were stored at -80°C. Refer to Figure 2
for a drawing of the rat neural anatomy.
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Figure 5. Rat Dorsal Root Ganglia Dissection.
(A) Rat dorsal spinal column exposed. Lumbar vertebrae are shaved.
(B) Rat dorsal spinal column clipped to expose underlying spinal cord.
(C) Rat spinal cord with laterally positioned Dorsal Root Ganglia (L3-L6) exposed.
Photographs kindly provided by Karl Andersen.

22

B. Zeyzus Johns

2.4

RNA isolation and quantification
Total RNA was extracted from Sprague-Dawley rat Dorsal Root Ganglia (DRG)

using the RNeasy kit with QIAShredder columns provided by Qiagen. RNA samples
underwent DNaseI treatment and were reverse transcribed using a poly-dT primer
(DNaseI, Super Script III RT, Invitrogen). Rat DRG cDNA samples were stored at -20°C
until further use.
Quantitative PCR analysis was performed on the DRG cDNA samples in
quadruplicate and was repeated at least once (Rotorgene2000 software, Corbett). cDNA
was amplified with Express Sybr GreenER (Invitrogen) and the following cycling
parameters were used: 50°C UDG incubation (2 Min), 95°C Hot start (2 Min), 35 cycles
of 95°C (20 sec), 68°C (30 sec), 65°C (60 sec). Samples were prepared on ice in flat cap
0.2mL PCR tubes, and the total reaction volume was 20µL. Ultra-pure molecular
biology grade water was used. Gene and species-specific primer pairs consisted of:

GAPDH forward (5’-ggctcatgaccacagtccatg-3’) and
GAPDH reverse (5’-gccatgaggtccaccacc-3’) (GenBank accession no. NM_017008),
TRPV1 forward (5’-ctatccaggaagttcaccgaatg-3’) and
TRPV1 reverse (5’- atccctcggaagaagaagtagactc-3’) (GenBank accession no.
NM_031982) (Table 2).

The “Noise Slope Correct” analysis tool was used for all reactions in order to
minimize background fluorescence. Melt curve analysis was performed for all QPCR
reactions to verify that each primer set amplified only one major product. Relative
TRPV1 mRNA expression in chronic constriction injury rats was analyzed using the
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comparative Ct method with GAPDH as the endogenous control [58, 59]. (See Results
section “TRPV1 mRNA quantification” for description). In accordance with this method,
primer efficiencies were determined similar for analysis, with a difference in efficiency
not exceeding 5%.
Amplified cDNAs were run on 2.5% agarose gels (1x buffer TAE) to verify
GAPDH and TRPV1 amplicon lengths. A standard ethidium bromide-staining protocol
was used. Ethidium bromide content did not exceed 6% of the total gel volume. Small
(35mL) gels were run at 75V for 85 minutes, medium (50mL) gels were run at 75V for
200 minutes, and large (80mL) gels ran at 90V for 280 minutes.

2.5

Statistical analysis
All statistical tests were performed using SPSS software. Assumptions of

ANOVA were met as indicated by Mauchly’s Test of Sphericity and Levine’s Test for
Equality of Variances. Significance of the F statistic was defined as p ≤ 0.05.
TRPV1 mRNA levels in right (ipsilateral to the nerve injury) DRG of CCI rats
was compared to right DRG of control (pooled) rats by performing a 1-Way ANOVA
with treatment as the between-subjects factor. Each level of the DRG was analyzed
separately. Analysis of TRPV1 mRNA levels in left DRG of CCI rats compared to left
DRG of the pooled control rats was performed the same way.
Statistical analysis of TRPV1 mRNA levels in the DRG was performed by a 2Way Repeated Measures ANOVA for each vertebral level (L3, L4, L5). The within
subjects factor was side of the spinal cord (left versus right DRG). The betweensubjects-factor was defined as the surgical condition: CCI or combined sham and unoperated controls.
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Lastly, TRPV1 mRNA levels were compared between DRG L3, L4 and L5 (both
right and left) of CCI rats by Repeated Measures ANOVA with. The within subjects
factor was level of DRG (L3, L4 and L5). The between-subjects-factor was defined as the
surgical condition: CCI or combined sham and un-operated controls.
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Table 2. Primer Sequences for GAPDH and TRPV1.

**GenBank Accession Numbers: NM_017008 (GAPDH), NM_031982 (TRPV1).
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2.6

Restriction enzyme digestion
Because the Sybr Green probe can inhibit the complete digestion of amplified

products with restriction enzymes, GAPDH and TRPV1 were amplified from rat DRG
cDNA by standard PCR. Samples were prepared on ice in flat cap 0.2mL PCR tubes, and
the total reaction volume was 20µL. Ultra-pure molecular biology grade water was used.
Manual 5 Prime Hot MasterMix (5 Prime) was used in place of the Express Sybr
GreenER mastermix (Invitrogen). Rat DRG cDNA was amplified in the Eppendorf
Mastercycler using the same GAPDH and TRPV1 primer sets as those used for QPCR
studies (Table 2). The following cycling parameters were used: 95°C Hot start (2 Min),
35 cycles of 95°C (20 sec), 68°C (30 sec), 65°C (60 sec).
Following amplification, cDNAs were run on 2.5% agarose gels as described in
section 2.4. The cDNA fragments were gel extracted and purified (QiaQuick Gel
Extraction Kit, Qiagen). GAPDH fragments were directly verified by restriction enzyme
digestion (GAPDH: BtgI), while TRPV1 fragments were re-amplified in order to increase
the template concentration for the digestion reaction (TRPV1: Tsp45I; enzymes supplied
by NEB). After the second round of amplification and prior to restriction enzyme
digestion, TRPV1 cDNA was run on a 2.5% agarose gel and gel purified to ensure purity.
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Chapter 3
RESULTS
3.1

Production of the chronic constriction injury
As early as 1 day post-operative, CCI rats presented with typical neuropathic

characteristics [50]. While walking and standing, the CCI rats applied minimal weight to
the affected hind limb and the toes were ventroflexed and close together instead of
dorsiflexed with toe spreading, which normally accompany such actions. As the
experiment progressed, weight bearing avoidance became more evident and limping was
common. Some rats even dragged the affected hind limb behind them while walking 11
days post-CCI surgery. A reduction in the width of the plantar surface of the right hind
paw was also observed on day 11, which is suggestive of muscle atrophy [50].

3.2

Mechanical allodynia
Chronic constriction injury rats exhibited nocifensor behavior in response to

calibrated monofilaments at both day 8 and day 11 post operative indicative of
mechanical allodynia (Fig 6). The mean normalized 50% withdrawal threshold of
chronic constriction injury rats was significantly more negative than that observed in the
un-operated controls at both post-operative time points (Kruskal-Wallis One-Way
ANOVA by Ranks: K-W = 4.47, p = 0.035 at day 8 post-surgery; K-W = 3.8, p = 0.042
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at day 11 post-surgery). There was no difference in mean normalized 50% withdrawal
threshold between the chronic constriction injury rats and the sham control rats at day 8
or day 11 post-surgery: K-W = 1.052, p = 0.305 at day 8 post-surgery; K-W = 2.4, p =
0.121 at day 11 post-surgery. Similarly, there was no difference in the mean normalized
50% withdrawal threshold between the un-operated and sham-operated control rats at day
8 or day 11: K-W = 1.83, p = 0.176 at day 8 post-surgery; K-W = 0, p = 1.0 at day 11
post-surgery.
Nocifensor behaviors were also recorded for each rat during each test session.
Because the recording of these observations was done on multiple rat subjects
simultaneously, these studies were not rigorously performed and the results represent
preliminary data. The number of CCI rats, sham controls and un-operated controls that
exhibited each behavior (guarding, paw licking and paw lifting) was recorded. Guarding
and paw lifting were only observed in CCI rats at day 8 and day 11 post-operative (Table
3). Excessive paw licking was most frequently observed in the CCI rats (Table 3).
Generalized muscle weakness suggestive of muscle atrophy was also observed in
CCI rats, as their right hind paw would slip through the wires of the mesh testing surface
[50].
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Figure 6. Mechanical Allodynia in the Right Hind Paw.
Bars represent the mean ± standard error of the mean (SEM) normalized
50% withdrawal threshold from calibrated Semmes-Weinstein
monofilaments (g) for each of the treatment groups; un-operated control,
sham-operated control, and chronic constriction injury (CCI). The more
negative a mean difference score, the lower the pain threshold in the right
hind paw. *Significant difference from un-operated control rats (KruskalWallis 1-way ANOVA by ranks; P≤0.05). Un-operated and sham-operated
control rats did not differ in normalized pain thresholds at day 8 or day 11
post-operative. Sample size representing each mean indicated on the
graph.
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3.3

Thermal hyperalgesia
Thermal hyperalgesia in chronic constriction injury rats was analyzed by

determining the withdraw latency from a radiant heat source. Chronic constriction injury
rats did not differ from either control group in their withdraw latency from heat (KruskalWallis 1-Way ANOVA by ranks) (Figure 7). At 8 days post-operative, the mean
normalized withdrawal latencies (pain score) calculated for CCI rats was no different
than that calculated for either the un-operated control rats or the sham-operated rats:
K-W value = 0.23, p = 0.631; K-W value = 0.92, p = 0.34 for comparison to un-operated
and sham-operated animals, respectively. Similarly, at 11 days post-operative, there was
no difference between the normalized difference scores for CCI rats and either the unoperated control rats or the sham-operated rats: K-W = 1.19, p = 0.28; K-W = 0.43, p =
0.52 for comparison to un-operated and sham-operated animals, respectively. There was
also no difference between the pain scores calculated for the un-operated and shamoperated control groups at day 8 or day 11: K-W = 0.32, p = 0.57; K-W = 0.43,
p = 0.51 for day 8 and day 11, respectively. Based on this analysis, the CCI animals did
not experience thermal hyperalgesia at day 8 or day 11.
Although the CCI rats did not test positive for thermal hyperalgesia, their pain
behaviors recorded during this assessment provide evidence of heightened pain
sensitivity in the right paw as compared to the left. Similar to that observed during the
mechanical pain test, only the CCI rats would guard their painful right paw by laying on
their left side in the test cubicle with their right hind paw in a protected position against
their flank. Paw lifting was only observed in CCI rats at day 8 and day 11 post-operative
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and excessive paw licking was more frequently observed in CCI rats 11 days postoperative (Table 3).
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3

Figure 7. Absence of Thermal Hyperalgesia in the Right
Hind Paw.
Bars represent the mean ± standard error of the mean (SEM) normalized
withdrawal latency from radiant heat for each of the treatment groups; unoperated control, sham-operated control, and chronic constriction injury
(CCI). The more negative a mean value, the lower the pain threshold in
the right hind paws. Un-operated control, sham-operated control and CCI
rats did not differ in normalized pain thresholds at day 8 or day 11 postoperative. Sample size representing each mean indicated on the graph.
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Table 3. Nocifensor Behaviors Recorded During the Mechanical and
Thermal Pain Assessments.

** Data represented as the number of animals that responded at least one time in each treatment group.
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3.4

Confirmation of the amplification of GAPDH and TRPV1 by
restriction enzyme digestion
PCR amplified GAPDH and TRPV1 cDNAs were digested with restriction

enzymes in order to verify amplified products. The results are shown in Figure 8. The
Tsp45I enzyme cuts the GAPDH amplicon into two asymmetric fragments with lengths
332bp and 136bp (Figure 8A). The 486bp uncut amplicon remains in the no-enzymecontrol lanes (lanes 5 and 8) and to a lesser extent in the experimental lanes (lanes 3, 4
and 6, 7). The 332bp cut fragment can be seen in the experimental lanes only.
Insufficient template concentration is responsible for the absence of the 136bp fragment.
The BtgI restriction enzyme cuts the 386bp full-length TRPV1 amplicon into two
fragments of non-equal lengths; 253bp and 133bp (Figure 8B). Faint bands representing
the 253bp fragment are observed in the experimental lanes only (lanes 3-8), and undigested fragments of length 386bp can be seen in the no-enzyme-control lanes (lanes 9,
10). Although TRPV1 cDNA was amplified twice, the template concentration was not
sufficient to observe the 133bp fragment.
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Figure 8. Restriction Enzyme Digested GAPDH and TRPV1.
(A) Agarose gel (2.5%) of digested GAPDH amplicon. Lane 1: 100bp DNA
Step Ladder, Lane 2: 25bp DNA Step Ladder, Lane 3,4,6,7: restriction enzyme
digested TRPV1 cDNA; box inset of digested GAPDH cDNA fragment (332bp)
and un-digested (468bp), Lane 5,8: no-enzyme-controls; box inset of undigested GAPDH cDNA (468bp).
(B) Agarose gel (2.5%) of digested TRPV1 amplicon. Lane 1: 100bp DNA
Step Ladder, Lane 2: 25bp DNA Step Ladder, Lane 3-8: restriction enzyme
digested TRPV1 cDNA; box inset of digested TRPV1 cDNA fragment (253bp),
Lane 9,10: no-enzyme-controls; box inset of un-digested TRPV1 cDNA
(386bp). Adjusted brightness/contrast in Adobe Photoshop (v5.02).
Data collected by Alex Ruiz.
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3.5

TRPV1 mRNA quantification
TRPV1 mRNA levels in DRG were examined by quantitative PCR and the

comparative Ct method [58, 59]. This method is based on the fact that the difference in
threshold cycles (∆Ct) between the gene of interest and a reference gene is proportional
to the relative mRNA level of the gene of interest (Fig 9A, B). Threshold cycle (Ct) was
the cycle number at which fluorescence crosses a threshold set by the user. Threshold
was set at 10-2.5 arbitrary fluorescence units, which samples during the log-linear
amplification phase, for all samples tested.
For each DRG sample, quantitative PCR was performed in quadruplicate and
repeated once at minimum. The resultant Ct values from the four replicates were
averaged, and a ∆Ct value was calculated as the difference between the average Ct of a
GAPDH mRNA sample and the average Ct of a TRPV1 sample. This calculation is
represented in the following formula:
∆Ct = (mean TRPV1 Ct) – (mean GAPDH Ct) for a DRG mRNA sample.
A smaller ∆Ct indicates an increase in TRPV1 mRNA. The ∆Ct values for each
treatment group (CCI, sham-operated control, un-operated control) were averaged, and
their means compared using SPSS statistical software as described in the methods.
GAPDH mRNA levels were similar in CCI, sham-operated and un-operated control rats
at day 9 and day 12 post-operative with a maximum variation of ±2 cycles. Because
there was no difference in pain scores for the un-operated and sham-operated control
groups from the pain assessments, the resultant ∆Ct values from these two groups were
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pooled. Thus, the mean TRPV1 mRNA level from control rats includes pooled values
from the un-operated and sham-operated control rats.
The ∆∆Ct values were calculated as the difference between the ∆Ct from a
control mRNA sample and the ∆Ct from a CCI mRNA sample. The ∆Ct from each CCI
mRNA sample was compared to each of the ∆Ct values from the sham and un-operated
control mRNA samples. This calculation is represented in the following formula:
∆∆Ct = (∆Ct from a control rat DRG) – (∆Ct from a CCI rat DRG).
A positive ∆ ∆Ct value indicates an increase in TRPV1 mRNA levels in CCI DRG
compared to control (unaffected) DRG. The ∆∆Ct values for each treatment group (CCI
and pooled controls) were transformed to fold changes in TRPV1 mRNA levels using the
following formula:
Fold Change = 2(∆∆Ct) with standard error of the mean = 2(∆∆Ct ± Std dev) .

The resultant fold changes were averaged and graphed to compare differences in
normalized TRPV1 transcript levels between different DRG spinal levels (L3, L4 and
L5).
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Figure 9. Quantitative PCR Data.
(A) Standard quantitative PCR plot generated by amplification of GAPDH (the
endogenous reference gene) and TRPV1 from mRNA extracted from L5 DRG of a
control rat. The difference in cycle threshold (∆Ct) is 6.7.
(B) Standard quantitative PCR plot generated by amplification of GAPDH and
TRPV1 from mRNA extracted from L5 DRG of a CCI rat. The ∆Ct is 5.9, almost
1 full cycle less than the control ∆Ct. This equates to almost double the amount of
starting TRPV1 transcript in CCI DRG compared to the control DRG.
Each fluorescence curve represents quadruplicate QPCR reactions.

38

B. Zeyzus Johns

3.6

TRPV1 mRNA levels 12 days post-surgery
Here we report that following chronic constriction injury (CCI) of the sciatic

nerve, TRPV1 mRNA levels in ipsilateral (right) Dorsal Root Ganglia (DRG) increased
(Figure 10). We assayed for changes in TRPV1 mRNA levels in response to sciatic
nerve injury at DRG levels L3, L4 and L5 due to varying afferent contributions from the
sciatic nerve [48, 49]. Relative to right DRG from control rats, TRPV1 mRNA levels are
elevated at all levels of the DRG in CCI rats (Figure 10A). Differences correspond to an
increase in relative TRPV1 mRNA expression of 2.6%, 3.1% and 10% in right DRG
from CCI rats as compared to controls for L3, L4 and L5, respectively. These differences
were not statistically different: L3: F1,8 = 0.25, p = 0.63; L4: F1,8 = 0.2, p = 0.67; L5:
F1,8 = 1.67, p = 0.24.
As predicted, there was no difference in TRPV1 mRNA levels in left DRG of CCI
rats compared to left DRG of pooled controls (Figure 10B). L3: F1,7 = 0.01, p = 0.92;
L4: F1,8 = 0.09, p = 0.77; L5: F1,8 = 0.76, p = 0.41.
Within CCI animals, TRPV1 transcript levels were higher in the DRG from the
side ipsilateral to the nerve injury (right DRG) compared to the side contralateral to the
nerve injury at 12 days post-operative (Figure 10C). L3 DRG increased by 3.3%, and L4
and L5 DRG experienced a 5.8 and 8.4 mean percent increase, respectively, relative to
left DRG at the same levels. These differences between the left and right DRG were not
statistically significant. L3: F2,5 = 0.05, p = 0.95; L4: F2,6 = 0.85, p = 0.47; L5: F2,6 =
4.29, p = 0.07.

39

B. Zeyzus Johns

A

B

C

40

B. Zeyzus Johns

Figure 10. Relative TRPV1 mRNA Levels 12 Days Post-CCI
Surgery.
(A) TRPV1 mRNA levels were increased non-significantly in DRG ipsilateral to
the nerve injury at all levels in CCI rats compared to ipsilateral DRG from pooled
controls. (See text for results of statistical tests).
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean represented
mean represented.
(B) TRPV1 mRNA levels did not differ in DRG contralateral to the nerve injury in
CCI rats compared to contralateral DRG from pooled controls.
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean represented
mean represented.
(C) TRPV1 mRNA was increased non-significantly in the DRG ipsilateral to the
nerve injury at all levels compared to contralateral DRG.
N=3 ∆Ct values for each mean represented.
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3.7

TRPV1 mRNA levels 9 days post-surgery
Differences in TRPV1 transcript levels were also examined 9 days post-surgery

(Figure 11). Relative to right DRG from control rats, there was no difference in TRPV1
mRNA levels for L4 and L5 DRG of CCI rats. There was an unexpected increase,
however, in the TRPV1 transcript level in CCI DRG L3 compared to control DRG L3
(Figure 11A). This difference was not statistically different: L3: F1,8 = 1.56, p = 0.25;
L4: F1,8 = 0.01, p = 0.93; L5: F1,8 = 0.14, p = 0.72.
As predicted, there was no difference in TRPV1 mRNA levels in left DRG of CCI
rats compared to left DRG of pooled controls (Figure 11B): L3: F1,8 = 0.61, p = 0.46;
L4: F1,8 = 4.75, p = 0.07; L5: F1,8 = 2.78, p = 0.14.
Within CCI animals, TRPV1 transcript levels were higher in the DRG from the
side ipsilateral to the nerve injury (right DRG) compared to the side contralateral to the
nerve injury (left DRG) at 9 days post-operative (Figure 11C). These differences were
not statistically significant: L3: F2,6 = 2.83, p = 0.14; L4: F2,6 = 1.75, p = 0.25; L5: F2,6
= 0.97, p = 0.43.
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Figure 11. Relative TRPV1 mRNA Levels 9 Days Post-CCI
Surgery.
(A) Relative mRNA levels in DRG ipsilateral to the nerve injury from CCI rats
compared to ipsilateral DRG from pooled controls. TRPV1 mRNA levels were
increased non-significantly in ipsilateral DRG at level 3 in CCI rats. There was
no difference in TRPV1 mRNA levels in L4 and L5 DRG from controls. (See
text for results of statistical tests).
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean
represented.
(B) TRPV1 mRNA levels did not differ in DRG contralateral to the nerve injury
in CCI rats compared to contralateral DRG from pooled controls.
N=6 ∆Ct values for each control, N=3 ∆Ct values for each CCI mean
represented.
(C) TRPV1 mRNA was increased non-significantly in the DRG ipsilateral to the
nerve injury at all levels compared to contralateral DRG.
N=3 ∆Ct values for each mean represented.
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3.8 TRPV1 mRNA levels in different spinal levels of DRG
We also compared TRPV1 mRNA levels in DRG at different spinal levels to
determine whether the magnitude of TRPV1 gene expression varies with spinal level
following sciatic nerve injury. The mRNA levels, when represented as Ct values, were
not statistically different between DRG 3, 4 and 5 at either day 9 or day 12 post-surgery:
day 9: F2,14 = 1.36, p = 0.29; day 12: F2,14 = 1.45, p = 0.27 (Repeated Measures
ANOVA). When normalized to transcript levels in ipsilateral DRG from control rats,
however, TRPV1 mRNA levels showed a marked increase in L5 DRG ipsilateral to the
nerve injury 12 days after surgery (Figure 12A). This difference equates to a 1.6-fold
increase in TRPV1 mRNA in L5 DRG, almost double the amount found in ipsilateral
DRG from control animals. There was no increase (fold change ≤ 1) in relative TRPV1
transcript levels in L3 and L4 ipsilateral DRG normalized to DRG from pooled controls:
L3: 0.5-fold change; L4: 0.4-fold change.
Within CCI animals, TRPV1 transcript levels were highest in the L5 DRG
ipsilateral to the nerve injury when normalized to transcript levels in contralateral DRG
from control rats at the same level 12 days post-surgery (Figure 12B). This difference
equates to a 1.5-fold increase in TRPV1 mRNA in L5 DRG. TRPV1 transcript levels
normalized to levels in contralateral DRG were not increased in L4 DRG, and there was a
decrease in transcript levels in L3 DRG: L3: -0.1-fold change; L4: 0.8-fold change.
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Figure 12. Relative TRPV1 Gene Expression Changes 12 Days
Post-CCI Surgery.
(A) TRPV1 mRNA levels were 1.6-fold higher in L5 DRG ipsilateral to the
nerve injury (right) from CCI rats compared to DRG from control rats.
TRPV1 transcript levels were not increased in L4 and L5 ipsilateral CCI
DRG.
N = 18 fold change values for each mean represented.
(B) Within CCI rats, TRPV1 mRNA levels were 1.5-fold higher in L5 DRG
ipsilateral to the nerve injury (right) compared to contralateral DRG (left). No
difference in TRPV1 mRNA levels between ipsilateral and contralateral L4
DRG. TRPV1 transcript levels are decreased in ipsilateral DRG 3 compared
to contralateral DRG 3.
N = 3 fold change values for each mean represented.
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Differences in TRPV1 transcript levels at different spinal levels of DRG were also
examined 9 days post-surgery (Figure 13). When normalized to transcript levels in
ipsilateral DRG from control rats, TRPV1 mRNA was unexpectedly increased in L3
ipsilateral DRG of CCI rats 12 days post-surgery (Figure 13A). This difference equates
to a 1.5-fold increase in TRPV1 mRNA in L3 DRG. The mean-fold differences in
normalized TRPV1 transcript levels for L4 and L5 ipsilateral DRG suggest a possible
down-regulation (fold change approaching 0 or ≤ 0) in TRPV1 gene expression: L4:
0.1-fold change; L5: -0.3-fold change.
Within CCI animals at 9 days post-surgery, TRPV1 transcript levels in ipsilateral
L5 DRG normalized to transcript levels in contralateral DRG were not increased (Figure
13B).
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Figure 13. Relative TRPV1 Gene Expression Changes 9
Days Post-CCI Surgery.
(A) TRPV1 mRNA levels were 1.5-fold higher in L3 DRG ipsilateral to
the nerve injury (right) from CCI rats compared to DRG from control rats.
TRPV1 transcript levels are decreased in ipsilateral DRG L4 and L5
compared to ipsilateral control DRG at the same levels.
N = 18 fold change values for each mean represented.
(B) Within CCI rats, TRPV1 mRNA levels were not increased for DRG
ipsilateral to the nerve injury (right) compared to contralateral DRG (left)
in L3, L4 and L5 DRG.
N = 3 fold change values for each mean represented.

48

B. Zeyzus Johns

3.9 Primer efficiency validation
For the ∆Ct calculation to be valid, it is essential that the amplification
efficiencies of the gene of interest and the reference gene be similar [58, 59]. GAPDH
and TRPV1 primer efficiency was assessed by observing how ∆Ct varies with template
dilution. A DRG cDNA preparation was diluted over a 2-fold range. Quantitative PCR
was performed on each dilution sample with sybr green probe (Express Sybr GreenER,
Invitrogen) and the primer sets listed in Table 2. The ∆Ct was determined as the
difference between the average GAPDH Ct and the average TRPV1 Ct. The log cDNA
dilutions were plotted against ∆Ct values. If the absolute value of the slope is close to 0,
the primer sets are considered approximately equal, and the ∆Ct calculation can be used
for relative mRNA quantification. The slope of the line is less than 0.1 at 0.0245;
therefore, the assumption that the efficiencies are similar holds true (Figure 14).
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Figure 14. Validation of the ∆∆Ct Calculation for mRNA
Quantification.
(A) Serial 2-fold serial dilutions of cDNA were amplified by quantitative PCR using
gene-specific primers for GAPDH and TRPV1. From left to right the diluted cDNA
preparations are as follows: GAPDH 1:2 (red), 1:4 (blue), 1:8 (black), 1:16 (purple),
1:32 (green) and TRPV11:2 (red), 1:4 (blue), 1:8 (black), 1:16 (purple), 1:32 (green).
The ∆Ct (Ct TRPV1-Ct GAPDH) was calculated for each cDNA dilution.
(B) Data were fit using least squares linear regression (n=5). The slope of the line is
less than 0.1 at 0.0245 and the primer efficiencies are considered similar.
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3.10 Pair-wise comparisons between TRPV1 gene expression and right
hind paw allodynia
Because each individual rat’s pain behavior and response was expected to be
variable due to inherent individual differences, the 50% withdrawal threshold and L5
DRG mRNA levels for all rats terminated on day 12 were compared within each
individual. As shown in Table 4, each of the three chronic constriction injury rats had a
negative normalized difference score, or pain score, indicating mechanical allodynia on
the day 11 test. Comparing the relative TRPV1 mRNA level in each individual CCI rat to
that of each of the different control rats reveals an increase in relative transcript levels in
the CCI rats in the majority of cases. Moreover, ∆∆Ct values that arise from comparison
of a CCI to a normal control resulted in the greatest value. Normal controls were defined
as those with a pain score of 0, indicating no difference in response to the calibrated
monofilaments for the left and right paw.
Although we observe an increase in TRPV1 mRNA in CCI DRG relative to
controls in the majority of cases, we did not find a correlation between the magnitude of
pain and mRNA level in ipsilateral DRG. Only two of the three CCI rats tested 11 days
post-surgery had substantially negative pain scores (pain score ≤ -7.0). CCI rat 3 had a
pain score of only -0.4, and thus was in less pain than CCI rats 1 and 2.
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Table 4: Pair-wise Comparisons Between 50% Withdrawal Threshold
(Mechanical Pain Score) and Relative TRPV1 mRNA Levels in Rats
with and without Chronic Constriction Injury; Level 5 DRG.

* See Results Section 3.5 for ∆∆Ct and fold change formulas.
Positive ∆∆Ct reflects an increase in TRPV1 transcript in CCI DRG relative to control DRG. Positive fold
changes representing an increase in TRPV1 mRNA level are represented in bold font.
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Chapter 4
DISCUSSION
The TRPV1 ion channel is a modulator of neuropathic pain. In peripheral nerve
terminals and in sensory ganglia, TRPV1 protein but not mRNA levels have been
demonstrated to increase in response to a nerve injury [40, 42]. In this thesis project,
TRPV1 mRNA levels in ipsilateral and contralateral Dorsal Root Ganglia (DRG) neurons
were compared at discrete vertebral levels after induction of chronic constriction injury
(CCI) on the sciatic nerve.

4.1

Increased TRPV1 mRNA levels
The results show that with an increase in mechanical pain sensitivity caused by

chronic constriction injury, TRPV1 mRNA levels increase 12 days post-surgery. It was
determined that the TRPV1 transcript level in L5 DRG on the side of the nerve injury in
CCI animals is increased compared to the transcript level in L5 DRG on the same side
(right) in the controls and to both the transcript level in L5 contralateral (left) DRG
within CCI rats. We interpret this to mean that TRPV1-expressing neurons in the DRG,
namely the small diameter C-fibers, are likely producing more TRPV1 transcript in
response to sciatic nerve injury. It may also be the case that neuron types that normally
do not express TRPV1, such as the large-sized DRG somata, are now induced to do so.
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Induction of TRPV1 protein expression through a phenotypic switch phenomenon is
evident in similar pain models [40, 60]. Considering that we did not detect any change in
TRPV1 mRNA levels in contralateral DRG cell bodies, it seems that there is no bilateral
affect of nerve injury on TRPV1 mRNA levels.
Our analysis of the increase in TRPV1 mRNA 12 days post-surgery is based on a
whole tissue analysis. Implicit is the fact that the change in TRPV1 mRNA level is not
uniform over the cells in the DRG. It is documented that only an estimated 10% of the
neurons in each ganglion express TRPV1 [60]. Rather, individual TRPV1 responsive
neurons are likely exhibiting substantial increases in mRNA level on a cell by cell basis.
Given that the TRPV1 transcript level at L5 is 1.6-fold higher in CCI animals than DRG
from controls, the overall TRPV1 expression is nearly doubling in CCI animals.
We expect that this increase in TRPV1 mRNA may contribute, in part, to the
production and maintenance of heightened pain sensitivity. Regulation of TRPV1 gene
expression may be occurring in many different ways. Inflammatory mediators such as
NGF can initiate p38 protein kinase activity in the DRG, which in turn, activates
transcription factors such as ATF-2, ELK-1 and CREB to increase transcription [61-63].
Protein kinases can also increase stability of the TRPV1 message and activate
translational factors [64]. More TRPV1 channels in the plasma membranes of terminal
nociceptors decreases the animals’ mechanical and thermal pain threshold [42]. A
decreased pain threshold leads to an increase in perceived pain. In this current study,
heightened pain response typical of mechanical allodynia was only observed for the right
hind paw of CCI rats, which is consistent with our finding of no bilateral affect of the
induction of pain on TRPV1 gene expression.
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4.2

Effect of anatomical DRG level on mRNA expression
We have demonstrated that the magnitude of the increase in TRPV1 mRNA level

is affected by anatomical DRG level. We analyzed TRPV1 mRNA levels at each DRG
level separately unlike other investigators who pooled RNA from all ipsilateral and
contralateral DRG for their analysis [27]. It is suggested that 98-99% of the somata of
primary afferent neurons projecting to the sciatic nerve reside in L4 and L5 DRG of rats,
while L3 and L6 contribute only 1.2% and 0.4% of the total, respectively [48,49].
Moreover, TRPV1 is expressed in small to medium diameter sensory neurons [20,60,65].
This neuron type is found in the greatest relative abundance in L5 DRG [48].
Considering the differing afferent contributions from the sciatic nerve to ganglia and the
different combinations of neuron types therein, it is not surprising that others did not find
a substantial change in TRPV1 mRNA levels after nerve injury. Although we did not
survey for mRNA levels in L6 DRG, we would expect no change in TRPV1 gene
expression as the contribution of the L6 spinal nerve to the sciatic nerve is low (5-10% of
L5) and highly variable, with some rats having no contribution from L6 (Figure 2) [49].
To our knowledge, we are providing the first report that shows the effect of
anatomical DRG level on the degree of increasing TRPV1 gene expression after injury to
the sciatic nerve. This observation need be considered by other investigators examining
changing gene expression in similar pain models. Together, our findings support the
hypothesis of an injury-induced gene expression mechanism for chronic pain, with
TRPV1 as a key player in this process.

55

B. Zeyzus Johns

4.3 Analysis of individuals
In addition to making an assessment of mean pain threshold and mean TRPV1
mRNA level, we chose to examine pain behavior and mRNA levels in L5 DRG on an
individual basis. Regardless of a precedent for variable responsiveness, the argument for
an increase in TRPV1 mRNA is supported by this individual analysis at day 12. The CCI
rats exhibit pain behaviors not seen in the controls and, in the majority of cases, have
higher TRPV1 transcript levels. The variation in individual ∆∆Ct that we observe was
expected, and is not unlike typical variation we would expect in humans, as each person’s
response to the same pain can be unique. As such, persons suffering from diseases
associated with neuropathic pain, such as CPSII [66], diabetes [67] or cancer [68] may
benefit from therapies designed to disrupt the induction of TRPV1 mRNA expression.
We were not able to demonstrate that the degree of pain measured in the CCI rats
correlates with an increase in TRPV1 mRNA. Not all (2 out of 3) of the CCI rats
assessed on day 11 post-surgery had substantially negative pain scores (-7.3). Our
assessment indicates that CCI rat 3 did not experience pain that was very unlike that
observed for the control rats, with a pain score of only -0.4. This rat was in less pain, yet
we determined its relative TRPV1 mRNA level exceeded that of the control rats, even
those controls with more negative pain scores. Furthermore, even though CCI rat 2 was
experiencing pain, the amount of TRPV1 transcript measured in L5 DRG did not exceed
levels in some (2 of the 5) control rats. These observations, although unexpected, are
likely due to variability in pain response for the controls. Attention, attitude and the
tightness of the ligature are factors that may have led to the failure to represent the
allodynic state of CCI rat 3.
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Implicit in this analysis is the idea that given a larger ‘normal’ control group
sample size (pain score of 0), we can predict an even greater observed pain response and
change in TRPV1 mRNA both at the level of the individual CCI rat and as a group.

4.4

Pain assessments
The results of the mechanical pain assessment indicate that the CCI rats

experienced mechanical allodynia at day 8 and day 11 post-operative. The mean
normalized difference score (pain score) for the CCI treatment group calculated by
comparing the total number of withdraws in the right paw to the left paw was
significantly more negative than the un-operated control group at both day 8 and day 11
post-surgery (Kruskal-Wallis One-Way ANOVA by Ranks). We found that the CCI
group had a more negative pain score than the sham-operated control group; however, the
difference was not significant at either day 8 or day 11 post-surgery. This may indicate,
especially at 8 days post-operative, that the sham operation created a slight pain-like state
that was detected by poking the rat’s hind paws with the monofilaments, although there is
no evidence of this in the literature. On the other hand, the negative pain score may also
represent variations in the pain response of the control rats to the painful stimulus. We
are not the first to report variable responses to a mechanical pain stimulus in un-operated
or sham-operated control rats. Analysis of our data directly followed methods used by
Dr. David Somers. In his published work, Dr. Somers reports a slightly negative (~-2.0)
difference score for his un-operated control group 12 days post-operative [52]. The
inherent variable responsiveness of control groups is magnified in a small sample size
like that used in this study (n=6 at 8 days post-surgery and n=3 at 12 days post-surgery).
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The results of the thermal pain assessment do not indicate that the CCI rats
experienced thermal hyperalgesia at day 8 or day 11 post-operative; yet, it is documented
elsewhere that rats should have a marked reduction in their thermal pain threshold as
early as the second post-operative day [50]. The thermal pain assessment tends to be less
reliable than the mechanical pain assessment, and is subject to more procedural problems.
For instance, habituating the animals on the heated surface tends to be far more
problematic than habituation on the metal grid. The rats experience anxiety that results in
frequent urination and defecation throughout the test session. The animals must be
removed from the plexi-glass surface, and the area must be cleaned thoroughly. The rats
are then put back in their testing cubicles and must be habituated again before recommencing with the testing.
Once the rats are relaxed in the testing cubicles, the radiant heat aperture must be
carefully aligned under their hind paws so that the laser irradiates a specific region of the
paw pad that is exclusively innervated by the sciatic nerve. The animal must remain still
during the irradiation. At the end of the trial, the administrator must distinguish whether
the rat displayed a painful response or a non-painful response. Although special care and
attention were given to completing this task with reproducible accuracy, it proved rather
difficult to the un-practiced administrator. Thus, the failure to accurately measure the
CCI rats’ hyperalgesic state is likely due to these potential sources of error. As shown in
Table 3 and Appendix Table 5, CCI rats exhibited nocifensor responses to the thermal
pain assessment that were not seen in the controls. Thus, although analysis of difference
scores did not support thermal hyperalgesia, rat pain-like behaviors observed during the
test sessions did.

58

B. Zeyzus Johns

4.5

Day 9 post-CCI surgery
TRPV1 mRNA levels were markedly increased in L3 DRG 9 days post-CCI

surgery. Although unexpected, our observation may be a genuine effect that is
meaningful to the development of the pain syndrome and/or to the increase that was
observed in L4 and L5 DRG 12 days post surgery. Although afferent contributions from
the sciatic nerve to L3 DRG are reportedly minimal [48, 49], it has been shown that
ligation of the L3-L5 spinal fibers in the sciatic nerve can influence the central axon
fibers in the dorsal horn of the spinal cord. One study that used the CCI pain model
found that labeling neurons on the uninjured, contralateral side of the nerve injury
revealed a connection between L3-L6 spinal segments [69]. Lissaur’s tract, or the
dorsolateral fasciculus, is a bundle of association fibers that connect different segments of
the posterior horn of the spinal cord. It is possible that axons that travel in Lissaur’s tract
may be responsible for the anatomical connections between the different spinal segments
in CCI rats [69].
Since sensory nerve fibers extend between different segments of the spinal cord, it
is possible that intersegmental changes can occur, and that these changes can alter the
Dorsal Root Ganglia pertaining to these spinal levels. Others have noted intersegmental
changes that occur with the CCI pain model. CCI-induced sciatic nerve lesion produces a
significant increase in spinal cord metabolic activity in lumbar regions L1-5 [70].
Following CCI, primary afferent nociceptors undergo reorganization that results in A-β
fibers sprouting to the third segment (L3) of the spinal cord [71]. Nerve sprouting was
detectable in CCI rats 1 week following surgery, was at its maximum 2 weeks postsurgery, and persisted for 6 months or more. These temporal events closely match
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clinical, mechanically-evoked pain responses of patients suffering from nerve injury [71].
At 9 days post-CCI surgery, we observe an increase in TRPV1 mRNA levels in L3 right
DRG of CCI rats relative to L3 right DRG in the controls that is not seen in L4 or L5
DRG. We believe this increase may be explained by the reorganization of primary
afferent fibers to the L3 spinal segment, and that these events may be responsible, in part,
for central sensitization.
It may also be the case that the L3 phenomenon was caused by a surgical mishap.
While performing the chronic constriction injury surgery, it was observed that some
animals differ anatomically in their sciatic nerve branching structure. More specifically,
differences in the presence or absence of a branch destined for muscle at mid-thigh levels
were observed. Care was taken by the investigator to keep the nerve area surrounding
this branch point clear. It is possible that a surgical knot was tied too closely to the branch
or, conversely, that after closing the surgical wound, a knot may have shifted such that
the branch point was constricted. Three sensory branches innervate the skin and/or
muscle at the level of the middle thigh; the lateral sural, the peroneal and the tibial nerves
[48]. All three of these branches contain neurons whose cell bodies are found in L3 DRG
[48]. Constriction of the branch point as described may have produced a painful state in
the muscle and skin of the thigh, and thus altered TRPV1 mRNA levels in L3 DRG.

4.6

Temporal relationship between nerve injury and TRPV1 mRNA
levels
At 12 days post-surgery, TRPV1 transcript levels were substantially elevated in

ipsilateral L5 DRG and only moderately elevated in L4 DRG of CCI rats compared to
transcript levels from control rat DRG. Chronic constriction injury of the sciatic nerve
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did not affect the amount of transcript, however, at 9 days post-surgery at these DRG
levels. Similar to the effect of time on the complex inter-segmental spinal interactions
that may be affecting events in L3 DRG, it is possible that a temporal relationship exists
between the initial nerve injury and the induction of increased TRPV1 transcript levels in
L4 and L5 DRG. One study that examined TRPV1 transcript levels separately in L4 and
L5 DRG 7 days post-operative supports our finding of no change in transcript levels at an
earlier time [42]. We, however, are the first to examine TRPV1 mRNA levels in rat
DRG using the CCI model at a later time.
The pain literature supports a precedent for time-dependent changes in CCIinduced events [71, 72, 73, 74, and 75]. Different mechanisms are involved at different
stages of pain development, where early mechanisms involving pro-inflammatory
cytokines like TNF-alpha and IL-6 are responsible for activating other pro-inflammatory
and pro-nociceptive mediators important for peripheral sensitization. Over time, these
early processes begin to operate in conjunction with longer-term gene expression
mechanisms that appear necessary for the maintenance of neuropathic pain. Our findings
support the notion that transcriptional regulation of TRPV1, like many other molecules
cited, is time-dependent. This may suggest that increasing TRPV1 protein levels are
necessary for peripheral sensitization and the development of acute pain, while increasing
TRPV1 mRNA levels is more important for central sensitization and the maintenance of
chronic pain [40, 41, and 42].
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Chapter 5
FUTURE DIRECTIONS
5.1

Elucidate neuronal cell population information
Quantitative PCR results show unequivocally that TRPV1 transcript levels

increase in ipsilateral DRG 12 days after injury to the sciatic nerve. Information about
the DRG cell population responsible for this increase, however, remains unknown. Backlabeling and in situ hybridization experiments would be useful procedures to address this
unknown. We have successfully used a retrograde axonal tracer, DiD, to label neurons
that project from the skin of the plantar surface of the rat’s hind paw to the DRG.
Fluorescent in situ hybridization (FISH) in DRG using a probe specific for TRPV1
mRNA could be used to identify the cells that express TRPV1. Using confocal
microscopy, the images produced from the back labeling and FISH experiments can be
superimposed to identify a TRPV1-expressing cell population with axonal extensions that
project into the sciatic nerve and into the affected area of the hind paw.
By performing these experiments in control and CCI, we would elucidate useful
information about changes in Dorsal Root Ganglia physiology in response to nerve
injury. We could determine the percentage of DRG neurons 1) that normally express
TRPV1 mRNA and receive afferents from the sciatic nerve and 2) that normally do not
express TRPV1 mRNA but are induced to do so following CCI. It has been documented
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that TRPV1 protein expression increases in the somata of DRG neurons that normally do
not express it [40]. It is conceivable that a changing gene expression phenotype is
driving the observed phenotypic protein switch.
Chronic constriction injury is a partial nerve injury that results in the death of
some axons that pass through the lesion site. Other axons retain the ability to transmit
electrical activity and perform axonal transport through the lesion site [71]. Data
surrounding the roles of injured and uninjured axons in neuropathic pain remain
controversial. It is documented that TRPV1 protein expression decreases in injured
DRG; yet, uninjured DRG neurons experience an increase in protein levels after CCI or
similar pain models [42, 71]. By probing for both TRPV1 and neuronal injury marker
transcript, we could determine whether the increase in TRPV1 mRNA level is
exclusively reserved for either injured or uninjured axons.
All of the proposed experiments should be performed on separate DRG from their
respective vertebral levels.

5.2

Analysis of other TRP genes and splice variants
The differential expression of other TRP genes that are known to function in the

pain pathway has yet to be explored in rat DRG. Among them, Transient Receptor
Potential Mellastatin 8 (TRPM8) has attracted interest for its involvement in the sensory
transduction of innocuous cold, inflammatory pain, menthol and other cooling agents [5,
6]. Transient Receptor Potential Ankyrin 1, likewise, has a known involvement in
inflammatory pain, and is activated by cold (T≤18°C), mustard oil and the pungent
chemical in garlic [5, 6]. It is documented that TRPM8 and TRPA1 mRNA levels
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increase in rat Dorsal Root Ganglia by chronic constriction injury of the sciatic nerve
[26]. Analysis of expression; however, was performed on pooled RNA from L4, L5 and
L6 DRG. It was determined in the present study that anatomical DRG level affects the
magnitude of the increase in TRPV1 mRNA levels. As such, expression of TRPA1 and
TRPM8 should be re-analyzed in each DRG level independently.
Evidence for alternative splicing of TRPV1 is documented in the literature;
however, little is known about the tissue distribution or the differential expression of
variants [6, 72]. Similar to the experiments in this project, analysis of TRPV1 splice
variant mRNA levels in different levels of dorsal root ganglia in response to neuropathic
pain needs to be performed.

Karl Andersen, a fellow graduate student, is currently

investigating the TRPV1b and TRPV1β variants in rat. Other variants have been
identified in rat that need to be examined, including TRPV1var and TRPV15’sv. Splice
variants of the canonical TRPM8 have also been reported in human [73]. Preliminary
results from Candice Kruth have identified a potential TRPM8 splice variant expressed in
rat DRG. Analysis of the expression of TRPV1 and TRPM8 alternate forms in each
Dorsal Root Ganglia level will further shed light on how the body encodes different types
of pain. The ultimate goal is to develop channel specific molecular antagonists that will
selectively block specific types of pain.
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APPENDIX

Appendix Table 1.
Day 9 ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an
ipsilateral CCI DRG sample to each ∆Ct from an ipsilateral control sample at
the same vertebral level. Red, bold fold changes represent a mathematical
increase in TRPV1 mRNA in CCI DRG relative to control. Fold change was
calculated 2(∆∆Ct±SEM).
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(Appendix Table 1 Continued)
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Appendix Table 2.
Day 12 ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an
ipsilateral CCI DRG sample to each ∆Ct from an ipsilateral control sample at
the same vertebral level. Red, bold fold changes represent an increase in
TRPV1 mRNA in CCI DRG relative to control. Fold change was calculated
2(∆∆Ct±SEM).
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(Appendix Table 2 Continued)
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Appendix Table 3.
All ∆∆Ct and fold-change data calculated by comparing each ∆Ct from an
ipsilateral DRG sample to each ∆Ct from a contralateral DRG sample at the
same vertebral level in the same animal. Red, bold fold changes represent a
mathematical increase in TRPV1 mRNA in ipsilateral DRG relative to
contralateral. Fold change was calculated 2(∆∆Ct±SEM).
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(Appendix Table 3 Continued)
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Appendix Table 4. Nocifensor Behaviors Recorded During the
Mechanical Pain Assessment.
Nocifensor behaviors were recorded for each rat during the mechanical pain
assessment. Guarding refers to contact avoidance between the affected (right)
hind limb and the wire mesh floor. The occurrence of paw licking was recorded
for the right hind paw after application of the pain stimulus. Paw lifting refers to
the rat holding its affected hind paw above the testing surface after application of
the stimulus (5-10s). X = positive for the pain behavior.

CCI Neuropathy
Day 8 Post-Operative
Rat
1
2
3
4
5
6

Guarding
X
X
---------

Paw Licking
X
----X
X
---

Paw Lifting
X
X
X
X
X
X

Guarding
X
X
---

Paw Licking
X
X
---

Paw Lifting
X
X
---

Day 11 Post-Operative
Rat
1
2
3

Sham Control
Day 8 Post-Operative
Rat
1
2
3
4
5
6

Guarding
-------------

Paw Licking
--X
---------

Paw Lifting
-------------

Guarding
-------

Paw Licking
-------

Paw Lifting
-------

Day 11 Post-Operative
Rat
1
2
3

Un-operated Control
Day 8 Post-Operative
Rat

Guarding

Paw Licking
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1
2
3
4
5
6

-------------

------X
-----

-------------

Guarding
-------

Paw Licking
-------

Paw Lifting
-------

Day 11 Post-Operative
Rat
1
2
3

(Appendix Table 4 Continued)
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Appendix Table 5. Nocifensor Behaviors Recorded During the
Thermal Pain Assessment.
Nocifensor behaviors were recorded for each rat during the thermal pain
assessment. Guarding refers to contact avoidance between the affected (right)
hind limb and the heated testing surface. The occurrence of paw licking was
recorded in the right hind paw after heat irradiation. Paw lifting refers to the rat
holding its affected hind paw above the testing surface after application of the
stimulus (5-10s). X = positive for the pain behavior.

CCI Neuropathy
Day 8 Post-Operative
Rat
1
2
3
4
5
6

Guarding
X
X
----X
X

Paw Licking
X
X
X
-------

Paw Lifting
X
------X
---

Guarding
X
-----

Paw Licking
X
X
X

Paw Lifting
--X
X

Day 11 Post-Operative
Rat
1
2
3

Sham Control
Day 8 Post-Operative
Rat
1
2
3
4
5
6

Guarding
-------------

Paw Licking
X
--X
X
-----

Paw Lifting
-------------

Guarding
-------

Paw Licking
-------

Paw Lifting
-------

Day 11 Post-Operative
Rat
1
2
3

Un-operated Control
Day 8 Post-Operative
Rat

Guarding

Paw Licking
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1
2
3
4
5
6

-------------

X
-----------

-------------

Guarding
-------

Paw Licking
-------

Paw Lifting
-------

Day 11 Post-Operative
Rat
1
2
3

(Appendix Table 5 Continued)
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